Various strategies targeting EGFR, such as TKI inhibitors and monoclonal antibodies, are currently being tested in IBC clinical trials, in combination with standard adjuvant or neoadjuvant therapies, with some showing promising clinical benefit8,9. This evidence concerns the gene EGFR and inflammatory breast carcinoma.